MFG
SUPN icon

Mendota Financial Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Mendota Financial Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$156 – 1065
2024
Q3 		$156 Buy
+5
New +$156 ﹤0.01% 729
2023
Q2 		– Sell
-1,415
Closed -$45.7K – 376
2023
Q1 		$45.7K Buy
+1,415
New +$54.4K 0.05% 145

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Mendota Financial Group's SUPN Position: Q4 2024 in Review

Mendota Financial Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2024, closing a stake of 5 shares — an estimated $156 sold.

Mendota Financial Group first reported a position in SUPN in Q1 2023 and held it in 2 quarters. The position peaked at $45.7K in Q1 2023. 294 funds tracked by Wall St. Rank hold SUPN as of Q4 2024.

  • Mendota Financial Group reported no remaining Supernus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Mendota Financial Group sold 5 Supernus Pharmaceuticals shares in Q4 2024, an estimated $156.
  • Mendota Financial Group first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Mendota Financial Group's Supernus Pharmaceuticals position peaked at $45.7K in Q1 2023.
  • 294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2024.

Based on Mendota Financial Group's 13F filing for Q4 2024, filed 14 Jan 2025.